Germany · Delayed Price · Currency is EUR Vaxcyte Company Description
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants.
The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria.
The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020.
Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
| Country | United States |
| Founded | 2013 |
| Industry | Biological Products, Except Diagnostic Substances |
| Employees | 414 |
| CEO | Grant Pickering |
Contact Details
Address: 825 Industrial Road San Carlos, Delaware 94070 United States | |
| Phone | 650 837 0111 |
| Website | vaxcyte.com |
Stock Details
| Ticker Symbol | 5VA |
| Exchange | Munich Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Grant Pickering | Chief Executive Officer |
| Andrew Guggenhime | Chief Financial Officer |
| James Wassil | Chief Operating Officer |